Skip to main content
SpringerLink
Log in

Treatment-Resistant Panic Disorder

  • Chapter
  • First Online:
Treatment Resistance in Psychiatry

Abstract

Panic disorder is a common and chronic psychiatric condition. Its treatment response is suboptimal, meaning that only one-third of the patients are able to stabilize to a panic-free state during follow-up. Panic disorder and its suboptimal treatment responses indeed significantly interfered with the individual’s functions and life qualities.

In this systemic review, we wish to define treatment-resistant panic disorder and to discuss its related biopsychosocial risk factors involved in resistance. We also summarized the underlying potential pathophysiology in terms of treatment resistance, including genetic susceptibility, brain function alterations, hypothalamus-pituitary-adrenal (HPA) axis dysregulation, and long-term systemic inflammation. The current available pharmacological options to manage treatment-resistant panic disorder include augmentation or adjunctive combination strategies. As well, non-pharmacological interventions including cognitive-behavioral therapy may be used in either first-line or adjunctive approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006;368(9540):1023–32.

    Article  PubMed  Google Scholar 

  2. Klein DF. Panic disorder. Lancet. 1999;353(9149):326–7.

    Article  CAS  PubMed  Google Scholar 

  3. Association AP. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980. p. 230–2.

    Google Scholar 

  4. Asmundson GJ, Taylor S, Smits JA. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depress Anxiety. 2014;31(6):480–6.

    Article  PubMed  Google Scholar 

  5. Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. p. 119–21.

    Book  Google Scholar 

  6. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.

    Article  PubMed  Google Scholar 

  7. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415–24.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med/Am Coll Occup Environ Med. 2001;43(3):218–25.

    Article  CAS  Google Scholar 

  10. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86.

    Article  PubMed  Google Scholar 

  11. Lynskey MT, Strang J. The global burden of drug use and mental disorders. Lancet. 2013;382(9904):1540–2.

    Article  PubMed  Google Scholar 

  12. Wang PS, Angermeyer M, Borges G, Bruffaerts R, Tat Chiu W, DE Girolamo G, et al. Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):177–85.

    PubMed  PubMed Central  Google Scholar 

  13. Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):603–13.

    Article  PubMed  Google Scholar 

  14. Batelaan NM, de Graaf R, Spijker J, Smit JH, van Balkom AJ, Vollebergh WA, et al. The course of panic attacks in individuals with panic disorder and subthreshold panic disorder: a population-based study. J Affect Disord. 2010;121(1–2):30–8.

    Article  PubMed  Google Scholar 

  15. Cowley DS, Flick SN, Roy-Byrne PP. Long-term course and outcome in panic disorder: a naturalistic follow-up study. Anxiety. 1996;2(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  16. Hirschfeld RM. Panic disorder: diagnosis, epidemiology, and clinical course. J Clin Psychiatry. 1996;57(Suppl 10):3–8. discussion 9–10

    PubMed  Google Scholar 

  17. Katschnig H, Amering M. The long-term course of panic disorder and its predictors. J Clin Psychopharmacol. 1998;18(6 Suppl 2):6S–11S.

    Article  CAS  PubMed  Google Scholar 

  18. Swoboda H, Amering M, Windhaber J, Katschnig H. The long-term course of panic disorder – an 11 year follow-up. J Anxiety Disord. 2003;17(2):223–32.

    Article  PubMed  Google Scholar 

  19. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness – course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17(3):173–9.

    Article  PubMed  Google Scholar 

  20. Practice guideline for the treatment of patients with panic disorder. Work group on panic disorder. American Psychiatric Association. Am J Psychiatry. 1998;155(5 Suppl):1–34.

    Google Scholar 

  21. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39.

    Article  PubMed  CAS  Google Scholar 

  22. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567–96.

    Article  CAS  PubMed  Google Scholar 

  23. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84.

    Article  CAS  PubMed  Google Scholar 

  24. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3(4):171–99.

    Article  PubMed  Google Scholar 

  25. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248–312.

    Article  PubMed  Google Scholar 

  26. Batelaan NM, de Graaf R, Penninx BW, van Balkom AJ, Vollebergh WA, Beekman AT. The 2-year prognosis of panic episodes in the general population. Psychol Med. 2010;40(1):147–57.

    Article  CAS  PubMed  Google Scholar 

  27. Wittchen HU, Nocon A, Beesdo K, Pine DS, Hofler M, Lieb R, et al. Agoraphobia and panic. Prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother Psychosom. 2008;77(3):147–57.

    Article  PubMed  Google Scholar 

  28. de Jonge P, Roest AM, Lim CC, Florescu SE, Bromet EJ, Stein DJ, et al. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety. 2016;33(12):1155–77.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162(6):1179–87.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Francis JL, Weisberg RB, Dyck IR, Culpepper L, Smith K, Orlando Edelen M, et al. Characteristics and course of panic disorder and panic disorder with agoraphobia in primary care patients. Prim Care Companion J Clin Psychiatry. 2007;9(3):173–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Katon WJ. Clinical practice. Panic disorder. N Engl J Med. 2006;354(22):2360–7.

    Article  CAS  PubMed  Google Scholar 

  32. Ammar G, Naja WJ, Pelissolo A. Treatment-resistant anxiety disorders: a literature review of drug therapy strategies. Encephale. 2015;41(3):260–5.

    Article  CAS  PubMed  Google Scholar 

  33. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805–14.

    Article  CAS  PubMed  Google Scholar 

  34. Menezes GB, Fontenelle LF, Mululo S, Versiani M. Treatment-resistant anxiety disorders: social phobia, generalized anxiety disorder and panic disorder. Rev Bras Psiquiatr. 2007;29(Suppl 2):S55–60.

    Article  PubMed  Google Scholar 

  35. Stein DJ, Seedat S. Unresolved questions about treatment-resistant anxiety disorders. CNS Spectr. 2004;9(10):715.

    Article  PubMed  Google Scholar 

  36. Gaynes BN. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry. 2009;70(Suppl 6):10–5.

    Article  PubMed  Google Scholar 

  37. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry. 2015;20:1142–50.

    Article  CAS  PubMed  Google Scholar 

  38. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16–22.

    PubMed  Google Scholar 

  39. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T, et al. Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol. 2011;79(3):406–20.

    Article  PubMed  Google Scholar 

  40. Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT, et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry. 2014;19(1):122–8.

    Article  CAS  PubMed  Google Scholar 

  41. Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, et al. Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety. 2009;26(10):922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Payne LA, White KS, Gallagher MW, Woods SW, Shear MK, Gorman JM, et al. Second-stage treatments for relative nonresponders to cognitive behavioral therapy (Cbt) for panic disorder with or without agoraphobia-continued Cbt versus Ssri: a randomized controlled trial. Depress Anxiety. 2016;33(5):392–9.

    Article  CAS  PubMed  Google Scholar 

  43. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(Suppl 22):29–34.

    PubMed  Google Scholar 

  44. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(Suppl 12):5–9.

    PubMed  Google Scholar 

  45. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59(Suppl 8):47–54.

    PubMed  Google Scholar 

  46. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003;64(Suppl 15):40–5.

    PubMed  Google Scholar 

  47. Bandelow B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr. 2006;11(10 Suppl 12):21–8.

    Article  PubMed  Google Scholar 

  48. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67(9):1428–34.

    Article  PubMed  Google Scholar 

  49. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153(10):1293–300.

    Article  CAS  PubMed  Google Scholar 

  50. Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011;79(6):806–13.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ramsawh HJ, Weisberg RB, Dyck I, Stout R, Keller MB. Age of onset, clinical characteristics, and 15-year course of anxiety disorders in a prospective, longitudinal, observational study. J Affect Disord. 2011;132(1–2):260–4.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sibrava NJ, Beard C, Bjornsson AS, Moitra E, Weisberg RB, Keller MB. Two-year course of generalized anxiety disorder, social anxiety disorder, and panic disorder in a longitudinal sample of African American adults. J Consult Clin Psychol. 2013;81(6):1052–62.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. J Clin Psychiatry. 2015;76(3):267–78.

    Article  PubMed  Google Scholar 

  54. Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A. Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcome. Psychol Med. 2007;37(10):1493–502.

    PubMed  Google Scholar 

  55. Song HM, Kim JH, Heo JY, Yu BH. Clinical characteristics of the respiratory subtype in panic disorder patients. Psychiatry Investig. 2014;11(4):412–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Roberson-Nay R, Kendler KS. Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples. Psychol Med. 2011;41(11):2411–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Chen J, Tsuchiya M, Kawakami N, Furukawa TA. Non-fearful vs. fearful panic attacks: a general population study from the National Comorbidity Survey. J Affect Disord. 2009;112(1–3):273–8.

    Article  PubMed  Google Scholar 

  58. Goodwin RD, Hamilton SP. The early-onset fearful panic attack as a predictor of severe psychopathology. Psychiatry Res. 2002;109(1):71–9.

    Article  PubMed  Google Scholar 

  59. Nakamura M, Sugiura T, Nishida S, Komada Y, Inoue Y. Is nocturnal panic a distinct disease category? Comparison of clinical characteristics among patients with primary nocturnal panic, daytime panic, and coexistence of nocturnal and daytime panic. J Clin Sleep Med. 2013;9(5):461–7.

    PubMed  PubMed Central  Google Scholar 

  60. Craske MG, Tsao JC. Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005;9(3):173–84.

    Article  PubMed  Google Scholar 

  61. Beidas RS, Suarez L, Simpson D, Read K, Wei C, Connolly S, et al. Contextual factors and anxiety in minority and European American youth presenting for treatment across two urban university clinics. J Anxiety Disord. 2012;26(4):544–54.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Clayton AH, Stewart RS, Fayyad R, Clary CM. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health. 2006;9(3):151–7.

    Article  CAS  PubMed  Google Scholar 

  63. Safren SA, Gonzalez RE, Horner KJ, Leung AW, Heimberg RG, Juster HR. Anxiety in ethnic minority youth. Methodological and conceptual issues and review of the literature. Behav Modif. 2000;24(2):147–83.

    Article  CAS  PubMed  Google Scholar 

  64. Nay W, Brown R, Roberson-Nay R. Longitudinal course of panic disorder with and without agoraphobia using the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychiatry Res. 2013;208(1):54–61.

    Article  PubMed  Google Scholar 

  65. Wetherell JL, Petkus AJ, Thorp SR, Stein MB, Chavira DA, Campbell-Sills L, et al. Age differences in treatment response to a collaborative care intervention for anxiety disorders. Br J Psychiatry. 2013;203(1):65–72.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Biederman J, Faraone SV, Hirshfeld-Becker DR, Friedman D, Robin JA, Rosenbaum JF. Patterns of psychopathology and dysfunction in high-risk children of parents with panic disorder and major depression. Am J Psychiatry. 2001;158(1):49–57.

    Article  CAS  PubMed  Google Scholar 

  67. Biederman J, Rosenbaum JF, Bolduc EA, Faraone SV, Hirshfeld DR. A high risk study of young children of parents with panic disorder and agoraphobia with and without comorbid major depression. Psychiatry Res. 1991;37(3):333–48.

    Article  CAS  PubMed  Google Scholar 

  68. Hirshfeld-Becker DR, Biederman J, Henin A, Faraone SV, Dowd ST, De Petrillo LA, et al. Psychopathology in the young offspring of parents with bipolar disorder: a controlled pilot study. Psychiatry Res. 2006;145(2–3):155–67.

    Article  PubMed  Google Scholar 

  69. Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006;67(1):126–36.

    Article  PubMed  Google Scholar 

  70. Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A. Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol Med. 2007;37(10):1503–9.

    PubMed  Google Scholar 

  71. Weck F, Grikscheit F, Hofling V, Kordt A, Hamm AO, Gerlach AL, et al. The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. J Anxiety Disord. 2016;42:10–8.

    Article  PubMed  Google Scholar 

  72. Huppert JD, Kivity Y, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapist effects and the outcome-alliance correlation in cognitive behavioral therapy for panic disorder with agoraphobia. Behav Res Ther. 2014;52:26–34.

    Article  PubMed  Google Scholar 

  73. Zickgraf HF, Chambless DL, McCarthy KS, Gallop R, Sharpless BA, Milrod BL, et al. Interpersonal factors are associated with lower therapist adherence in cognitive-behavioural therapy for panic disorder. Clin Psychol Psychother. 2016;23(3):272–84.

    Article  PubMed  Google Scholar 

  74. Carrera M, Herran A, Ramirez ML, Ayestaran A, Sierra-Biddle D, Hoyuela F, et al. Personality traits in early phases of panic disorder: implications on the presence of agoraphobia, clinical severity and short-term outcome. Acta Psychiatr Scand. 2006;114(6):417–25.

    Article  CAS  PubMed  Google Scholar 

  75. Vohma U, Raag M, Toru I, Aluoja A, Maron E. Association between personality traits and escitalopram treatment efficacy in panic disorder. Nord J Psychiatry. 2017;71(6):433–40.

    Article  PubMed  Google Scholar 

  76. Marchesi C, De Panfilis C, Cantoni A, Fonto S, Giannelli MR, Maggini C. Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30(7):1240–5.

    Article  CAS  Google Scholar 

  77. Haug T, Nordgreen T, Ost LG, Tangen T, Kvale G, Hovland OJ, et al. Working alliance and competence as predictors of outcome in cognitive behavioral therapy for social anxiety and panic disorder in adults. Behav Res Ther. 2016;77:40–51.

    Article  PubMed  Google Scholar 

  78. Marchesi C, Cantoni A, Fonto S, Giannelli MR, Maggini C. The effect of temperament and character on response to selective serotonin reuptake inhibitors in panic disorder. Acta Psychiatr Scand. 2006;114(3):203–10.

    Article  CAS  PubMed  Google Scholar 

  79. Wachleski C, Salum GA, Blaya C, Kipper L, Paludo A, Salgado AP, et al. Harm avoidance and self-directedness as essential features of panic disorder patients. Compr Psychiatry. 2008;49(5):476–81.

    Article  PubMed  Google Scholar 

  80. Dusseldorp E, Spinhoven P, Bakker A, van Dyck R, van Balkom AJ. Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychother Psychosom. 2007;76(3):154–61.

    Article  PubMed  Google Scholar 

  81. Hazen AL, Walker JR, Eldridge GD. Anxiety sensitivity and treatment outcome in panic disorder. Anxiety. 1996;2(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  82. Ino K, Ogawa S, Kondo M, Imai R, Ii T, Furukawa TA, et al. Anxiety sensitivity as a predictor of broad dimensions of psychopathology after cognitive behavioral therapy for panic disorder. Neuropsychiatr Dis Treat. 2017;13:1835–40.

    Article  PubMed  PubMed Central  Google Scholar 

  83. McNally RJ. Anxiety sensitivity and panic disorder. Biol Psychiatry. 2002;52(10):938–46.

    Article  PubMed  Google Scholar 

  84. Park HJ, Kim EJ, Ku JI, Woo JM, Lee SH, Chung SK, et al. Psychological characteristics of early remitters in patients with panic disorder. Psychiatry Res. 2012;197(3):237–41.

    Article  PubMed  Google Scholar 

  85. Plehn K, Peterson RA. Anxiety sensitivity as a predictor of the development of panic symptoms, panic attacks, and panic disorder: a prospective study. J Anxiety Disord. 2002;16(4):455–74.

    Article  PubMed  Google Scholar 

  86. Poletti S, Radaelli D, Cucchi M, Ricci L, Vai B, Smeraldi E, et al. Neural correlates of anxiety sensitivity in panic disorder: a functional magnetic resonance imaging study. Psychiatry Res. 2015;233(2):95–101.

    Article  PubMed  Google Scholar 

  87. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998;59(Suppl 8):11–4. discussion 5–6

    PubMed  Google Scholar 

  88. Skodol AE, Geier T, Grant BF, Hasin DS. Personality disorders and the persistence of anxiety disorders in a nationally representative sample. Depress Anxiety. 2014;31(9):721–8.

    Article  PubMed  Google Scholar 

  89. Batelaan NM, ten Have M, van Balkom AJ, Tuithof M, de Graaf R. Anxiety disorders and onset of cardiovascular disease: the differential impact of panic, phobias and worry. J Anxiety Disord. 2014;28(2):252–8.

    Article  PubMed  Google Scholar 

  90. Carr RE. Panic disorder and asthma: causes, effects and research implications. J Psychosom Res. 1998;44(1):43–52.

    Article  CAS  PubMed  Google Scholar 

  91. Chen YH, Lin HC. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan. Acta Psychiatr Scand. 2011;123(1):55–61.

    Article  PubMed  Google Scholar 

  92. Player MS, Peterson LE. Anxiety disorders, hypertension, and cardiovascular risk: a review. Int J Psychiatry Med. 2011;41(4):365–77.

    Article  PubMed  Google Scholar 

  93. Smitherman TA, Kolivas ED, Bailey JR. Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache. 2013;53(1):23–45.

    Article  PubMed  Google Scholar 

  94. Roy-Byrne P, Stein MB, Russo J, Craske M, Katon W, Sullivan G, et al. Medical illness and response to treatment in primary care panic disorder. Gen Hosp Psychiatry. 2005;27(4):237–43.

    Article  PubMed  Google Scholar 

  95. Goodwin RD. Self-reported hay fever and panic attacks in the community. Ann Allergy Asthma Immunol. 2002;88(6):556–9.

    Article  PubMed  Google Scholar 

  96. Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry. 2007;64(10):1153–60.

    Article  PubMed  Google Scholar 

  97. Meuret AE, Kroll J, Ritz T. Panic disorder comorbidity with medical conditions and treatment implications. Annu Rev Clin Psychol. 2017;13:209–40.

    Article  PubMed  Google Scholar 

  98. Chou PH, Lin CH, Loh el W, Chan CH, Lan TH. Panic disorder and risk of stroke: a population-based study. Psychosomatics. 2012;53(5):463–9.

    Article  PubMed  Google Scholar 

  99. Tully PJ, Turnbull DA, Beltrame J, Horowitz J, Cosh S, Baumeister H, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. 2015;45(14):2909–20.

    Article  CAS  PubMed  Google Scholar 

  100. Weissman MM, Markowitz JS, Ouellette R, Greenwald S, Kahn JP. Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey. Am J Psychiatry. 1990;147(11):1504–8.

    Article  CAS  PubMed  Google Scholar 

  101. Claudia P, Andrea C, Chiara C, Stefano L, Giuseppe M, Vincenzo DL, et al. Panic disorder in menopause: a case control study. Maturitas. 2004;48(2):147–54.

    Article  PubMed  Google Scholar 

  102. Bandelow B, Sojka F, Broocks A, Hajak G, Bleich S, Ruther E. Panic disorder during pregnancy and postpartum period. Eur Psychiatry. 2006;21(7):495–500.

    Article  PubMed  Google Scholar 

  103. Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry. 1994;55(12):539–42.

    CAS  PubMed  Google Scholar 

  104. Flint AJ, Gagnon N. Diagnosis and management of panic disorder in older patients. Drugs Aging. 2003;20(12):881–91.

    Article  CAS  PubMed  Google Scholar 

  105. Kukoyi O, Argo TR, Carnahan RM. Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. Pharmacotherapy. 2005;25(3):435–7.

    Article  PubMed  Google Scholar 

  106. Sansone RA, Sansone LA. Exacerbation of panic disorder symptoms following Vicodin exposure. Gen Hosp Psychiatry. 2002;24(6):448–9.

    Article  PubMed  Google Scholar 

  107. Zealberg JJ, Lydiard RB, Christie S. Exacerbation of panic disorder in a woman treated with trimethoprim-sulfamethoxazole. J Clin Psychopharmacol. 1991;11(2):144–5.

    Article  CAS  PubMed  Google Scholar 

  108. Farber GA, Levin T, White CA. A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. Gen Hosp Psychiatry. 2005;27(5):329–37.

    Article  PubMed  Google Scholar 

  109. Abadie D, Essilini A, Fulda V, Gouraud A, Yelehe-Okouma M, Micallef J, et al. Drug-induced panic attacks: analysis of cases registered in the French pharmacovigilance database. J Psychiatr Res. 2017;90:60–6.

    Article  PubMed  Google Scholar 

  110. Barrera TL, Graham DP, Dunn NJ, Teng EJ. Influence of trauma history on panic and posttraumatic stress disorder in returning veterans. Psychol Serv. 2013;10(2):168–76.

    Article  PubMed  Google Scholar 

  111. Liebowitz MR. Panic disorder as a chronic illness. J Clin Psychiatry. 1997;58(Suppl 13):5–8.

    PubMed  Google Scholar 

  112. Moreno-Peral P, Conejo-Ceron S, Motrico E, Rodriguez-Morejon A, Fernandez A, Garcia-Campayo J, et al. Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. J Affect Disord. 2014;168:337–48.

    Article  PubMed  Google Scholar 

  113. Pollack MH. Long-term management of panic disorder. J Clin Psychiatry. 1990;51(Suppl):11–3. discussion 50–3

    PubMed  Google Scholar 

  114. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003;8(8 Suppl 1):17–30.

    Article  PubMed  Google Scholar 

  115. Scheibe G, Albus M. Predictors and outcome in panic disorder: a 2-year prospective follow-up study. Psychopathology. 1997;30(3):177–84.

    Article  CAS  PubMed  Google Scholar 

  116. Roy-Byrne P, Sherbourne C, Miranda J, Stein M, Craske M, Golinelli D, et al. Poverty and response to treatment among panic disorder patients in primary care. Am J Psychiatry. 2006;163(8):1419–25.

    Article  PubMed  Google Scholar 

  117. Roy-Byrne PP, Russo J, Cowley DS, Katon WJ. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry. 2003;64(4):383–9.

    Article  PubMed  Google Scholar 

  118. Asselmann E, Stender J, Grabe HJ, Konig J, Schmidt CO, Hamm AO, et al. Assessing the interplay of childhood adversities with more recent stressful life events and conditions in predicting panic pathology among adults from the general population. J Affect Disord. 2017;225:715–22.

    Article  PubMed  Google Scholar 

  119. Cannon DM, Klaver JM, Klug SA, Carlson PJ, Luckenbaugh DA, Ichise M, et al. Gender-specific abnormalities in the serotonin transporter system in panic disorder. Int J Neuropsychopharmacol. 2013;16(4):733–43.

    Article  CAS  PubMed  Google Scholar 

  120. Jacob C, Domschke K, Gajewska A, Warrings B, Deckert J. Genetics of panic disorder: focus on association studies and therapeutic perspectives. Expert Rev Neurother. 2010;10(8):1273–84.

    Article  CAS  PubMed  Google Scholar 

  121. Lueken U, Straube B, Wittchen HU, Konrad C, Strohle A, Wittmann A, et al. Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. J Neural Transm. 2015;122(1):135–44.

    Article  CAS  PubMed  Google Scholar 

  122. Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, et al. Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. Am J Med Genet Part B, Neuropsychiatr Genet. 2012;159B(7):786–93.

    Article  CAS  Google Scholar 

  123. Saeki Y, Watanabe T, Ueda M, Saito A, Akiyama K, Inoue Y, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2009;65(7):685–91.

    Article  CAS  PubMed  Google Scholar 

  124. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123(1–3):308–11.

    Article  CAS  PubMed  Google Scholar 

  125. Domschke K, Braun M, Ohrmann P, Suslow T, Kugel H, Bauer J, et al. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol. 2006;9(3):349–55.

    Article  CAS  PubMed  Google Scholar 

  126. Domschke K, Ohrmann P, Braun M, Suslow T, Bauer J, Hohoff C, et al. Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. Psychiatry Res. 2008;163(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  127. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry. 1993;54(Suppl):4–11. discussion 2–4

    PubMed  Google Scholar 

  128. He Q, Yuan Z, Liu Y, Zhang J, Yan H, Shen L, et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics. 2017;27(8):279–84.

    Article  CAS  PubMed  Google Scholar 

  129. Fonzo GA, Ramsawh HJ, Flagan TM, Sullivan SG, Letamendi A, Simmons AN, et al. Common and disorder-specific neural responses to emotional faces in generalised anxiety, social anxiety and panic disorders. Br J Psychiatry: J Ment Sci. 2015;206(3):206–15.

    Article  Google Scholar 

  130. Hahn T, Kircher T, Straube B, Wittchen HU, Konrad C, Strohle A, et al. Predicting treatment response to cognitive behavioral therapy in panic disorder with agoraphobia by integrating local neural information. JAMA Psychiat. 2015;72(1):68–74.

    Article  Google Scholar 

  131. Holtz K, Pane-Farre CA, Wendt J, Lotze M, Hamm AO. Brain activation during anticipation of interoceptive threat. NeuroImage. 2012;61(4):857–65.

    Article  PubMed  Google Scholar 

  132. Mechias ML, Etkin A, Kalisch R. A meta-analysis of instructed fear studies: implications for conscious appraisal of threat. NeuroImage. 2010;49(2):1760–8.

    Article  PubMed  Google Scholar 

  133. Reinecke A, Thilo K, Filippini N, Croft A, Harmer CJ. Predicting rapid response to cognitive-behavioural treatment for panic disorder: the role of hippocampus, insula, and dorsolateral prefrontal cortex. Behav Res Ther. 2014;62:120–8.

    Article  PubMed  Google Scholar 

  134. De Cort K, Schroijen M, Hurlemann R, Claassen S, Hoogenhout J, Van den Bergh O, et al. Modeling the development of panic disorder with interoceptive conditioning. Eur Neuropsychopharmacol. 2017;27(1):59–69.

    Article  PubMed  CAS  Google Scholar 

  135. de Carvalho MR, Dias GP, Cosci F, de-Melo-Neto VL, Bevilaqua MC, Gardino PF, et al. Current findings of fMRI in panic disorder: contributions for the fear neurocircuitry and CBT effects. Expert Rev Neurother. 2010;10(2):291–303.

    Article  PubMed  Google Scholar 

  136. de Carvalho MR, Rozenthal M, Nardi AE. The fear circuitry in panic disorder and its modulation by cognitive-behaviour therapy interventions. World J Biol Psychiatry. 2010;11(2 Pt 2):188–98.

    Article  PubMed  Google Scholar 

  137. Lueken U, Straube B, Konrad C, Wittchen HU, Strohle A, Wittmann A, et al. Neural substrates of treatment response to cognitive-behavioral therapy in panic disorder with agoraphobia. Am J Psychiatry. 2013;170(11):1345–55.

    Article  PubMed  Google Scholar 

  138. Melzig CA, Michalowski JM, Holtz K, Hamm AO. Anticipation of interoceptive threat in highly anxiety sensitive persons. Behav Res Ther. 2008;46(10):1126–34.

    Article  PubMed  Google Scholar 

  139. Asami T, Hayano F, Nakamura M, Yamasue H, Uehara K, Otsuka T, et al. Anterior cingulate cortex volume reduction in patients with panic disorder. Psychiatry Clin Neurosci. 2008;62(3):322–30.

    Article  PubMed  Google Scholar 

  140. Uchida RR, Del-Ben CM, Busatto GF, Duran FL, Guimaraes FS, Crippa JA, et al. Regional gray matter abnormalities in panic disorder: a voxel-based morphometry study. Psychiatry Res. 2008;163(1):21–9.

    Article  PubMed  Google Scholar 

  141. Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry. 1996;53(4):323–31.

    Article  CAS  PubMed  Google Scholar 

  142. Abelson JL, Khan S, Liberzon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety. 2007;24(1):66–76.

    Article  PubMed  Google Scholar 

  143. de Oliveira AR, Reimer AE, Reis FM, Brandao ML. Conditioned fear response is modulated by a combined action of the hypothalamic-pituitary-adrenal axis and dopamine activity in the basolateral amygdala. Eur Neuropsychopharmacol. 2013;23(5):379–89.

    Article  PubMed  CAS  Google Scholar 

  144. Herman JP, McKlveen JM, Solomon MB, Carvalho-Netto E, Myers B. Neural regulation of the stress response: glucocorticoid feedback mechanisms. Braz J Med Biol Res. 2012;45(4):292–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Ising M, Hohne N, Siebertz A, Parchmann AM, Erhardt A, Keck M. Stress response regulation in panic disorder. Curr Pharm Des. 2012;18(35):5675–84.

    Article  CAS  PubMed  Google Scholar 

  146. Petrowski K, Wintermann GB, Kirschbaum C, Bornstein SR. Dissociation between ACTH and cortisol response in DEX-CRH test in patients with panic disorder. Psychoneuroendocrinology. 2012;37(8):1199–208.

    Article  CAS  PubMed  Google Scholar 

  147. Jovanovic T, Phifer JE, Sicking K, Weiss T, Norrholm SD, Bradley B, et al. Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology. 2011;36(10):1540–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Michopoulos V, Norrholm SD, Stevens JS, Glover EM, Rothbaum BO, Gillespie CF, et al. Dexamethasone facilitates fear extinction and safety discrimination in PTSD: a placebo-controlled, double-blind study. Psychoneuroendocrinology. 2017;83:65–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Leyton M, Belanger C, Martial J, Beaulieu S, Corin E, Pecknold J, et al. Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls. Biol Psychiatry. 1996;40(5):353–60.

    Article  CAS  PubMed  Google Scholar 

  150. Wichmann S, Kirschbaum C, Bohme C, Petrowski K. Cortisol stress response in post-traumatic stress disorder, panic disorder, and major depressive disorder patients. Psychoneuroendocrinology. 2017;83:135–41.

    Article  CAS  PubMed  Google Scholar 

  151. Coryell W, Noyes R Jr, Reich J. The prognostic significance of HPA-axis disturbance in panic disorder: a three-year follow-up. Biol Psychiatry. 1991;29(2):96–102.

    Article  CAS  PubMed  Google Scholar 

  152. Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry. 1996;153(1):69–73.

    Article  CAS  PubMed  Google Scholar 

  153. Abelson JL, Liberzon I, Young EA, Khan S. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry. 2005;62(6):668–75.

    Article  PubMed  Google Scholar 

  154. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 1997;22(5):332–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  155. Monfils MH, Cowansage KK, LeDoux JE. Brain-derived neurotrophic factor: linking fear learning to memory consolidation. Mol Pharmacol. 2007;72(2):235–7.

    Article  CAS  PubMed  Google Scholar 

  156. Ou LC, Yeh SH, Gean PW. Late expression of brain-derived neurotrophic factor in the amygdala is required for persistence of fear memory. Neurobiol Learn Mem. 2010;93(3):372–82.

    Article  CAS  PubMed  Google Scholar 

  157. Rattiner LM, Davis M, French CT, Ressler KJ. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci. 2004;24(20):4796–806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci. 2003;91(4):267–70.

    Article  CAS  PubMed  Google Scholar 

  159. Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(5):658–63.

    Article  CAS  Google Scholar 

  160. Han EJ, Kim YK, Hwang JA, Kim SH, Lee HJ, Yoon HK, et al. Evidence for association between the brain-derived neurotrophic factor gene and panic disorder: a novel haplotype analysis. Psychiatry Investig. 2015;12(1):112–7.

    Article  CAS  PubMed  Google Scholar 

  161. Suliman S, Hemmings SM, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci. 2013;7:55.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Chen K, Wang N, Zhang J, Hong X, Xu H, Zhao X, et al. Is the Val66Met polymorphism of the brain-derived neurotrophic factor gene associated with panic disorder? A meta-analysis. Asia Pac Psychiatry. 2017;9(2). https://doi.org/10.1111/appy.12228. Epub 2015 Dec 21.

    Article  Google Scholar 

  163. Lam P, Cheng CY, Hong CJ, Tsai SJ. Association study of a brain-derived neurotrophic factor (Val66Met) genetic polymorphism and panic disorder. Neuropsychobiology. 2004;49(4):178–81.

    Article  CAS  PubMed  Google Scholar 

  164. Casarotto PC, de Bortoli VC, Correa FM, Resstel LB, Zangrossi H Jr. Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA. Int J Neuropsychopharmacol. 2010;13(5):573–82.

    Article  CAS  PubMed  Google Scholar 

  165. Casarotto PC, Santos PC, Lucas GA, Biojone C, Pobbe RL, Vilela-Costa HH, et al. BDNF-TRKB signaling system of the dorsal periaqueductal gray matter is implicated in the panicolytic-like effect of antidepressant drugs. Eur Neuropsychopharmacol. 2015;25(6):913–22.

    Article  CAS  PubMed  Google Scholar 

  166. Strohle A, Stoy M, Graetz B, Scheel M, Wittmann A, Gallinat J, et al. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. Psychoneuroendocrinology. 2010;35(3):364–8.

    Article  PubMed  CAS  Google Scholar 

  167. Candore G, Caruso C, Jirillo E, Magrone T, Vasto S. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr Pharm Des. 2010;16(6):584–96.

    Article  CAS  PubMed  Google Scholar 

  168. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.

    Article  CAS  PubMed  Google Scholar 

  169. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9(3):218–32.

    Article  CAS  PubMed  Google Scholar 

  170. Rohleder N. Acute and chronic stress induced changes in sensitivity of peripheral inflammatory pathways to the signals of multiple stress systems – 2011 Curt Richter Award Winner. Psychoneuroendocrinology. 2012;37(3):307–16.

    Article  CAS  PubMed  Google Scholar 

  171. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom Med. 2014;76(3):181–9.

    Article  PubMed  Google Scholar 

  172. Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology. 2017;42(1):254–70.

    Article  CAS  PubMed  Google Scholar 

  173. Vogelzangs N, Beekman AT, de Jonge P, Penninx BW. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry. 2013;3:e249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865–71.

    Article  PubMed  Google Scholar 

  175. Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety. 2009;26(5):447–55.

    Article  CAS  PubMed  Google Scholar 

  176. Belem da Silva CT, Costa MA, Bortoluzzi A, Pfaffenseller B, Vedana F, Kapczinski F, et al. Cytokine levels in panic disorder: evidence for a dose-response relationship. Psychosom Med. 2017;79(2):126–32.

    CAS  PubMed  Google Scholar 

  177. Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BW. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology. 2013;38(9):1573–85.

    Article  CAS  PubMed  Google Scholar 

  178. Koh KB, Lee Y. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother Psychosom. 2004;73(5):286–92.

    Article  PubMed  Google Scholar 

  179. Freire RC, Machado S, Arias-Carrion O, Nardi AE. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets. 2014;13(6):1057–65.

    Article  CAS  PubMed  Google Scholar 

  180. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327–40.

    Article  CAS  PubMed  Google Scholar 

  181. Nardi AE, Machado S, Almada LF, Paes F, Silva AC, Marques RJ, et al. Clonazepam for the treatment of panic disorder. Curr Drug Targets. 2013;14(3):353–64.

    CAS  PubMed  Google Scholar 

  182. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355–62.

    Article  PubMed  Google Scholar 

  183. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71(7):839–54.

    Article  CAS  PubMed  Google Scholar 

  184. Wang HR, Woo YS, Bahk WM. The potential role of atypical antipsychotics in the treatment of panic disorder. Hum Psychopharmacol. 2014;29(5):405–13.

    Article  CAS  PubMed  Google Scholar 

  185. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999;19(1):86–93.

    Article  CAS  PubMed  Google Scholar 

  186. Imai H, Tajika A, Chen P, Pompoli A, Guaiana G, Castellazzi M, et al. Azapirones versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2014;(9):CD010828. https://doi.org/10.1002/14651858.CD010828.pub2.

  187. Patterson B, Van Ameringen M. Augmentation strategies for treatment-resistant anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2016;33(8):728–36.

    Article  PubMed  Google Scholar 

  188. Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009;70(11):1563–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Physician. 2002;66(8):1477–84.

    PubMed  Google Scholar 

  190. Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs. 2015:1–14.

    Google Scholar 

  191. Perna G, Guerriero G, Caldirola D. Emerging drugs for panic disorder. Expert Opin Emerg Drugs. 2011;16(4):631–45.

    Article  CAS  PubMed  Google Scholar 

  192. Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs. 2015;24(4):491–505.

    Article  CAS  PubMed  Google Scholar 

  193. Hellbom E, Humble M. Panic disorder treated with the antihistamine chlorpheniramine. Ann Allergy Asthma Immunol. 2003;90(3):361. author reply -2

    Article  PubMed  Google Scholar 

  194. Sansone RA, Sears CD. The successful use of meclizine in panic disorder. J Clin Psychiatry. 2004;65(9):1285–6.

    Article  PubMed  Google Scholar 

  195. Mataix-Cols D, Fernandez de la Cruz L, Monzani B, Rosenfield D, Andersson E, Perez-Vigil A, et al. D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiat. 2017;74(5):501–10.

    Article  Google Scholar 

  196. Ray SM, Kious BM. Sustained resolution of panic disorder, agoraphobia, and generalized anxiety disorder with a single ketamine infusion: a case report. Prim Care Companion CNS Disord. 2016;18(4).

    Google Scholar 

  197. Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V. Xenon in the treatment of panic disorder: an open label study. J Transl Med. 2017;15(1):137.

    Article  PubMed  PubMed Central  Google Scholar 

  198. McHugh RK, Smits JA, Otto MW. Empirically supported treatments for panic disorder. Psychiatr Clin North Am. 2009;32(3):593–610.

    Article  PubMed  Google Scholar 

  199. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011;11:200.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Rodrigues H, Figueira I, Goncalves R, Mendlowicz M, Macedo T, Ventura P. CBT for pharmacotherapy non-remitters – a systematic review of a next-step strategy. J Affect Disord. 2011;129(1–3):219–28.

    Article  PubMed  Google Scholar 

  201. Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P. Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? Depress Anxiety. 2011;28(7):560–7.

    Article  PubMed  Google Scholar 

  202. Wang Z, Whiteside SPH, Sim L, Farah W, Morrow AS, Alsawas M, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:1049–56.

    Article  PubMed  PubMed Central  Google Scholar 

  203. Campbell-Sills L, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Stein MB. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. Depress Anxiety. 2016;33(12):1099–106.

    Article  PubMed  Google Scholar 

  204. Markowitz JC, Lipsitz J, Milrod BL. Critical review of outcome research on interpersonal psychotherapy for anxiety disorders. Depress Anxiety. 2014;31(4):316–25.

    Article  PubMed  PubMed Central  Google Scholar 

  205. Meuret AE, Wolitzky-Taylor KB, Twohig MP, Craske MG. Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions. Behav Ther. 2012;43(2):271–84.

    Article  PubMed  Google Scholar 

  206. Kim B, Lee SH, Kim YW, Choi TK, Yook K, Suh SY, et al. Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorder. J Anxiety Disord. 2010;24(6):590–5.

    Article  PubMed  Google Scholar 

  207. Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, et al. Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009;26(7):601–6.

    Article  PubMed  Google Scholar 

  208. Horst F, Den Oudsten B, Zijlstra W, de Jongh A, Lobbestael J, De Vries J. Cognitive behavioral therapy vs. eye movement desensitization and reprocessing for treating panic disorder: a randomized controlled trial. Front Psychol. 2017;8:1409.

    Article  PubMed  PubMed Central  Google Scholar 

  209. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016;4:CD011004.

    PubMed  Google Scholar 

  210. Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M, Clarkin J, et al. A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry. 2007;164(2):265–72.

    Article  PubMed  Google Scholar 

  211. Li H, Wang J, Li C, Xiao Z. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. Cochrane Database Syst Rev. 2014;9:CD009083.

    Google Scholar 

  212. George MS, Padberg F, Schlaepfer TE, O’Reardon JP, Fitzgerald PB, Nahas ZH, et al. Controversy: repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-compulsive disorder, panic, posttraumatic stress disorder). Brain Stimul. 2009;2(1):14–21.

    Article  PubMed  Google Scholar 

  213. Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. J Affect Disord. 2013;144(1–2):153–9.

    Article  PubMed  Google Scholar 

  214. Ironside M, O’Shea J, Cowen PJ, Harmer CJ. Frontal cortex stimulation reduces vigilance to threat: implications for the treatment of depression and anxiety. Biol Psychiatry. 2016;79(10):823–30.

    Article  PubMed  Google Scholar 

  215. Ravindran AV, da Silva TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. J Affect Disord. 2013;150(3):707–19.

    Article  PubMed  Google Scholar 

  216. Pilkington K, Kirkwood G, Rampes H, Cummings M, Richardson J. Acupuncture for anxiety and anxiety disorders – a systematic literature review. Acupunct Med. 2007;25(1–2):1–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan

    Mu-Hong Chen & Shih-Jen Tsai

  2. School of Medicine, National Yang-Ming University, Taipei, Taiwan

    Mu-Hong Chen & Shih-Jen Tsai

Authors
  1. Mu-Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shih-Jen Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, MH., Tsai, SJ. (2019). Treatment-Resistant Panic Disorder. In: Kim, YK. (eds) Treatment Resistance in Psychiatry. Springer, Singapore. https://doi.org/10.1007/978-981-10-4358-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4358-1_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4357-4

  • Online ISBN: 978-981-10-4358-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation